Leerink Partners has maintained its Outperform rating on Geron (NASDAQ:GERN) Corporation (NASDAQ: GERN), with a steady price target of $7.00.
The firm's stance comes in anticipation of the first full quarter of sales for Geron's Rytelo, expected to be reported with the third quarter 2024 earnings.
Leerink's analysis of third-party data sources, such as IQVIA/Symphony, reveals that the first year of drug launches in the hematology/oncology sector typically sees an average revenue capture rate of approximately 90%, though this figure can vary widely.
Rytelo, which is the brand name for the drug imetelstat, is being used to treat lower-risk myelodysplastic syndrome (LR-MDS). Leerink's confidence in the drug's market potential is reinforced by its therapeutic profile and label, positive feedback from a MEDACorp survey, and historical commercial successes in the treatment of LR-MDS.
In other recent news, Geron Corporation has seen promising early adoption trends for its new drug, Rytelo, approved for lower-risk myelodysplastic syndromes. Analyst firm Goldman Sachs (NYSE:GS) reaffirmed its Buy rating on the company, estimating global peak sales of Rytelo could reach $1.2 billion. Similarly, Leerink Partners initiated coverage with an Outperform rating, projecting peak sales of approximately $1.4 billion in the United States.
In a strategic development, Geron Corporation appointed Jim Ziegler as Executive Vice President, Chief Commercial Officer, leveraging his extensive experience in the biopharmaceutical industry to enhance Geron's commercial strategy, particularly for Rytelo.
On the research front, Geron Corporation is engaged in a Phase 3 clinical trial for imetelstat in relapsed/refractory myelofibrosis, further solidifying its focus on blood cancer treatments. As of mid-2024, Geron's financial position remains robust, with $430 million in cash and equivalents, and projected operating expenses for 2024 estimated between $270 million and $280 million.
InvestingPro Insights
To complement Leerink Partners' optimistic outlook on Geron Corporation (NASDAQ:GERN), recent data from InvestingPro provides additional context to the company's financial position and market performance.
InvestingPro data shows that Geron's revenue growth has been impressive, with a 205.11% increase over the last twelve months as of Q2 2024. This aligns with Leerink's expectations for a successful launch of Rytelo. Moreover, the company's market capitalization stands at $2.61 billion, reflecting investor confidence in its potential.
However, it's important to note that Geron is not yet profitable, with a negative operating income of $227.37 million in the last twelve months. This is not unusual for biotech companies in the early stages of drug commercialization, and it underscores the importance of Rytelo's success for Geron's financial future.
InvestingPro Tips highlight that analysts anticipate sales growth in the current year, which supports Leerink's positive stance on Rytelo's market potential. Additionally, Geron holds more cash than debt on its balance sheet, providing financial flexibility as it navigates the critical early stages of Rytelo's launch.
For investors seeking a deeper understanding of Geron's prospects, InvestingPro offers 11 additional tips that could provide valuable insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.